Table 1.
Cohort demographics from UPENN CNDR and UK-ADC
| UPENN CNDR |
UK-ADC |
|||
|---|---|---|---|---|
| FTLD-TDP | LATE-NC | FTLD-TDP | LATE-NC | |
| n | 33 | 30 | 8 | 14 |
| Age at death (mean ± SD) | 66.6 ± 9.3 | 88.6 ± 6.4 | 62.9 ± 9.8 | 90.9 ± 8.5 |
| Clinical diagnosis at last exama | ||||
| No documented impairment | 0 | 0 | 2 | 0 |
| Mild cognitive impairment | 0 | 3 | 0 | 0 |
| Vascular dementia | 0 | 1 | 0 | 2 |
| Probable Alzheimer’s disease | 2 | 26 | 0 | 12 |
| bvFTD-FTLD | 2 | 0 | 2 | 0 |
| bvFTD-FTLD/MND | 5 | 0 | 2 | 0 |
| bvFTD-FTLD/PPA | 5 | 0 | 2 | 0 |
| Genetics | ||||
| C9orf72 expansion | 11 | 0 | N/A | N/A |
| GRN variant | 7 | 0 | N/A | N/A |
| TBK1 variant | 1 | 0 | N/A | N/A |
| VCP mutation | 0 | 0 | 1 | N/A |
| FTLD-TDP type | ||||
| Type A or B | 23 | N/A | 4 | N/A |
| Type C | 6 | N/A | 2 | N/A |
| Type D | 0 | N/A | 1 | N/A |
| Type E | 4 | N/A | 1 | N/A |
| LATE-NC stage | ||||
| Stage 0 | N/A | 0 | N/A | 0 |
| Stage 1 | N/A | 0 | N/A | 0 |
| Stage 2 | N/A | 2 | N/A | 9 |
| Stage 3 | N/A | 28 | N/A | 5 |
| Intermediate/high ADNCb | 4 | 28 | 0 | 0 |
bvFTD = behavioural variant FTD; MND = motor neuron disease; N/A = not assessed; PPA = primary progressive aphasia.
a
For clinical diagnostic criteria and definitions, see ‘Materials and methods’ section.
b
According to NIA-AA neuropathological criteria (Hyman and Trojanowski, 1997).